Numinus Completes First MDMA Administration in PTSD Trial

Dr. Joe Flanders, PhD, VP, Psychology  at Numinus Wellness Inc, a Canadian-based company at the forefront of advancing safe, effective, and innovative psychedelic-assisted therapies, and  assistant instructor with the McGill University Psychology department, discusses  the enrollment of the first clinical trial volunteer as part of the next implementation phase in the clinical trial “A multi-site open-label extension study of MDMA-assisted psychotherapy for PTSD (MAPPUSX).”   The trial is sponsored by the Multidisciplinary Association for Psychedelic Studies (MAPS) and organized by MAPS Public Benefit Corporation (MAPS PBC).   MAPPUSX is an extension of the parent study MAPP1 by MAPS, which investigated the safety of MDMA-assisted therapy for treating severe PTSD.    

Dr. Joe Flanders is a licensed psychologist, with an active practice in psychotherapy and psychedelic-assisted psychotherapy. He holds certifications as a Mindfulness-Based Stress Reduction and Mindfulness-Based Cognitive Therapy teacher and teacher-trainer. He is trained to deliver Ketamine-Assisted Psychotherapy and currently in training to deliver MDMA for PTSD (MAPS USA).

Joe has been on a life-long journey in the pursuit of the most effective approaches for cultivating well-being – his own and that of his clients. In the last decade of that journey, Joe has been acting as the Founder and Director of Mindspace, a centre for well-being with several locations and over 35 mental health professionals in Montreal.